Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

KRAS G12A

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

Related tests:

therascreen® KRAS RGQ PCR Kit (5)

therascreen® KRAS RGQ PCR Kit (5)

KRAS G12A	Colorectal Cancer	KRAS G12A	Colorectal Cancer	cetuximab Resistant: B - Late Trials cetuximab Resistant : B	cetuximab Resistant: B - Late Trials cetuximab Resistant : B
KRAS G12A	Colorectal Cancer	KRAS G12A	Colorectal Cancer	panitumumab Resistant: B - Late Trials panitumumab Resistant : B	panitumumab Resistant: B - Late Trials panitumumab Resistant : B
KRAS G12A	Chronic Myeloid Leukemia	KRAS G12A	Chronic Myeloid Leukemia	GT19077 Sensitive: C3 – Early Trials GT19077 Sensitive : C3	GT19077 Sensitive: C3 – Early Trials GT19077 Sensitive : C3
KRAS G12A	Ovarian Serous Adenocarcinoma	KRAS G12A	Ovarian Serous Adenocarcinoma	VS-6766 + VS-6063 Sensitive: C3 – Early Trials VS-6766 + VS-6063 Sensitive : C3	VS-6766 + VS-6063 Sensitive: C3 – Early Trials VS-6766 + VS-6063 Sensitive : C3
KRAS G12A	Hepatocellular Cancer	KRAS G12A	Hepatocellular Cancer	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3
KRAS G12A	Non Small Cell Lung Cancer	KRAS G12A	Non Small Cell Lung Cancer	erlotinib Resistant: C3 – Early Trials erlotinib Resistant : C3	erlotinib Resistant: C3 – Early Trials erlotinib Resistant : C3
KRAS G12A	Non Small Cell Lung Cancer	KRAS G12A	Non Small Cell Lung Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
KRAS G12A	Non Small Cell Lung Cancer	KRAS G12A	Non Small Cell Lung Cancer	VS-6766 Sensitive: C3 – Early Trials VS-6766 Sensitive : C3	VS-6766 Sensitive: C3 – Early Trials VS-6766 Sensitive : C3
KRAS G12A	Non Small Cell Lung Cancer	KRAS G12A	Non Small Cell Lung Cancer	regorafenib Sensitive: C4 – Case Studies regorafenib Sensitive : C4	regorafenib Sensitive: C4 – Case Studies regorafenib Sensitive : C4
KRAS G12A	Lymphoma	KRAS G12A	Lymphoma	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D
KRAS G12A	Multiple Myeloma	KRAS G12A	Multiple Myeloma	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D
KRAS G12A	Acute Myelogenous Leukemia	KRAS G12A	Acute Myelogenous Leukemia	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D
KRAS G12A	Chronic Lymphocytic Leukemia	KRAS G12A	Chronic Lymphocytic Leukemia	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D	GT19077 Sensitive: D – Preclinical GT19077 Sensitive : D
KRAS G12A	Colorectal Cancer	KRAS G12A	Colorectal Cancer	sunitinib Resistant: D – Preclinical sunitinib Resistant : D	sunitinib Resistant: D – Preclinical sunitinib Resistant : D